Am J Perinatol 2025; 42(09): 1206-1212
DOI: 10.1055/a-2480-3163
Original Article

Impact of Cannabis Legalization on Umbilical Cord Tissue Tetrahydrocannabinol Levels

Kimberly Spence
1   Division of Neonatal-Perinatal Medicine, SSM Cardinal Glennon Children's Hospital, Saint Louis, Missouri
2   Division of Neonatology, Department of Pediatrics, Saint Louis University, Saint Louis, Missouri
,
Sarah Milota
1   Division of Neonatal-Perinatal Medicine, SSM Cardinal Glennon Children's Hospital, Saint Louis, Missouri
2   Division of Neonatology, Department of Pediatrics, Saint Louis University, Saint Louis, Missouri
,
Paula Buchanan
2   Division of Neonatology, Department of Pediatrics, Saint Louis University, Saint Louis, Missouri
,
Nirja Acharya
1   Division of Neonatal-Perinatal Medicine, SSM Cardinal Glennon Children's Hospital, Saint Louis, Missouri
2   Division of Neonatology, Department of Pediatrics, Saint Louis University, Saint Louis, Missouri
,
Amit M. Mathur
1   Division of Neonatal-Perinatal Medicine, SSM Cardinal Glennon Children's Hospital, Saint Louis, Missouri
2   Division of Neonatology, Department of Pediatrics, Saint Louis University, Saint Louis, Missouri
› Author Affiliations

Funding None.

Abstract

Objective

This study aimed to assess the impact of cannabis legalization on both qualitative and quantitative umbilical cord tissue tetrahydrocannabinol (THC) rates and concentrations as a proxy for fetal exposure.

Study Design

This is a retrospective, observational study of umbilical cord tissue THC levels in a single center, comparing THC exposure rates and concentration levels before and after cannabis legalization in the state of Illinois, Epoch 1 (October 1, 2018–June 30, 2019, pre-legalization) and Epoch 2 (July 1, 2019–August 31, 2021, post-legalization).

Results

A total of 811 umbilical cords were analyzed during epoch 1 and 2,170 during epoch 2. A higher percentage of umbilical cord tissue tested positive for THC in Epoch 2 compared with Epoch 1 (46.2 vs. 40.6%; p < 0.01). Mean THC levels were 51% higher in umbilical cord tissue in Epoch 2 versus Epoch 1 (6.2 ng/g vs. 4.1 ng/g; p < 0.001).

Conclusion

Legalization of recreational cannabis was associated with more fetuses exposed to THC and in higher concentrations.

Key Points

  • THC concentration can be measured in umbilical cord tissue after birth.

  • THC positivity in umbilical cord tissue can be used as a proxy for fetal exposure to cannabis.

  • Umbilical cord tissue THC concentration and rates of positivity increased with the legalization of cannabis.

Note

This manuscript is original and has not been previously published except in abstract format for Pediatric Academic Society 2024.




Publication History

Received: 19 July 2024

Accepted: 20 November 2024

Accepted Manuscript online:
21 November 2024

Article published online:
24 December 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 
  • References

  • 1 Volkow ND, Han B, Compton WM, McCance-Katz EF. Self-reported medical and nonmedical cannabis use among pregnant women in the United States. JAMA 2019; 322 (02) 167-169
  • 2 Metz TD, Silver RM, McMillin GA. et al. Prenatal marijuana use by self-report and umbilical cord sampling in a state with marijuana legalization. Obstet Gynecol 2019; 133 (01) 98-104
  • 3 Hutchings DE, Martin BR, Gamagaris Z, Miller N, Fico T. Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci 1989; 44 (11) 697-701
  • 4 Paul SE, Hatoum AS, Fine JD. et al. Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD study. JAMA Psychiatry 2021; 78 (01) 64-76
  • 5 Gunn JK, Rosales CB, Center KE. et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open 2016; 6 (04) e009986
  • 6 Marchand G, Masoud AT, Govindan M. et al. Birth outcomes of neonates exposed to marijuana in utero: a systematic review and meta-analysis. JAMA Netw Open 2022; 5 (01) e2145653
  • 7 Baranger DAA, Paul SE, Colbert SMC. et al. Association of mental health burden with prenatal cannabis exposure from childhood to early adolescence: longitudinal findings from the Adolescent Brain Cognitive Development (ABCD) Study. JAMA Pediatr 2022; 176 (12) 1261-1265
  • 8 Moore BF, Sauder KA, Shapiro ALB, Crume T, Kinney GL, Dabelea D. Fetal exposure to cannabis and childhood metabolic outcomes: The Healthy Start Study. J Clin Endocrinol Metab 2022; 107 (07) e2862-e2869
  • 9 El Marroun H, Tiemeier H, Steegers EA. et al. Intrauterine cannabis exposure affects fetal growth trajectories: the Generation R Study. J Am Acad Child Adolesc Psychiatry 2009; 48 (12) 1173-1181
  • 10 de Moraes Barros MC, Guinsburg R, de Araújo Peres C, Mitsuhiro S, Chalem E, Laranjeira RR. Exposure to marijuana during pregnancy alters neurobehavior in the early neonatal period. J Pediatr 2006; 149 (06) 781-787
  • 11 Ostrea Jr EM, Brady MJ, Parks PM, Asensio DC, Naluz A. Drug screening of meconium in infants of drug-dependent mothers: an alternative to urine testing. J Pediatr 1989; 115 (03) 474-477
  • 12 Montgomery D, Plate C, Alder SC, Jones M, Jones J, Christensen RD. Testing for fetal exposure to illicit drugs using umbilical cord tissue vs meconium. J Perinatol 2006; 26 (01) 11-14
  • 13 Wabuyele SL, Colby JM, McMillin GA. Detection of drug-exposed newborns. Ther Drug Monit 2018; 40 (02) 166-185
  • 14 Lozano J, García-Algar O, Vall O, de la Torre R, Scaravelli G, Pichini S. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit 2007; 29 (06) 711-734
  • 15 Wu F, Jensen TL, McMillin GA. Detection of in utero cannabis exposure in umbilical cord tissue by a sensitive liquid chromatography-tandem mass spectrometry method. Methods Mol Biol 2019; 1872: 211-222
  • 16 Jensen TL, Wu F, McMillin GA. Detection of in utero exposure to cannabis in paired umbilical cord tissue and meconium by liquid chromatography-tandem mass spectrometry. Clin Mass Spectrom 2019; 14 (Pt B): 115-123
  • 17 Schaneman B. Lack of standard, dubious business practices threaten to upend cannabis testing industry. MJBizDaily. Published January 4, 2021 . Accessed August 25, 2023 at: https://mjbizdaily.com/lack-of-standards-dubious-business-practices-threaten-to-upend-cannabis-testing-industry
  • 18 ElSohly MA, Chandra S, Radwan M, Majumdar CG, Church JC. A comprehensive review of cannabis potency in the United States in the last decade. Biol Psychiatry Cogn Neurosci Neuroimaging 2021; 6 (06) 603-606
  • 19 Jarlenski M, Shroff J, Terplan M, Roberts SCM, Brown-Podgorski B, Krans EE. Association of race with urine toxicology testing among pregnant patients during labor and delivery. JAMA Health Forum 2023; 4 (04) e230441
  • 20 Perlman NC, Cantonwine DE, Smith NA. Toxicology testing in a newborn ICU: does social profiling play a role?. Hosp Pediatr 2021; 11 (09) e179-e183
  • 21 Schoneich S, Plegue M, Waidley V. et al. Incidence of newborn drug testing and variations by birthing parent race and ethnicity before and after recreational cannabis legalization. JAMA Netw Open 2023; 6 (03) e232058
  • 22 Chasnoff IJ, Landress HJ, Barrett ME. The prevalence of illicit-drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida. N Engl J Med 1990; 322 (17) 1202-1206
  • 23 Roberts SC, Nuru-Jeter A. Universal screening for alcohol and drug use and racial disparities in child protective services reporting. J Behav Health Serv Res 2012; 39 (01) 3-16
  • 24 de Castro A, Jones HE, Johnson RE, Gray TR, Shakleya DM, Huestis MA. Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes. Ther Drug Monit 2011; 33 (04) 443-452
  • 25 Young-Wolff KC, Ray GT, Alexeeff SE. et al. Rates of prenatal cannabis use among pregnant women before and during the COVID-19 pandemic. JAMA 2021; 326 (17) 1745-1747
  • 26 Mehra K, Rup J, Wiese JL, Watson TM, Bonato S, Rueda S. Changes in self-reported cannabis use during the COVID-19 pandemic: a scoping review. BMC Public Health 2023; 23 (01) 2139